<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="618">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005692</url>
  </required_header>
  <id_info>
    <org_study_id>CM-002</org_study_id>
    <nct_id>NCT02005692</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Assess the DynaSense System</brief_title>
  <official_title>A Pilot Study to Assess the DynaSense System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leaf Healthcare, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centauri Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Leaf Healthcare, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to test the DynaSense system, which is a patient movement and
      orientation monitoring system. The study is intended to determine that:

        -  the DynaSense system identifies patients that are not turning adequately on their own
           and therefore require caregiver-assisted turns.

        -  the DynaSense system identifies patients that are turning adequately on their own and
           therefore do not require a caregiver-assisted turn.

        -  the DynaSense system helps ensure compliance with an institution's established patient
           turning protocol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Safety Primary Endpoint</measure>
    <time_frame>Subjects will be followed for the length of hospital stay which is expected to average 5 days, or until resolution of ADE.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The safety primary endpoint is to assess safety by documenting the number, type, and severity of side effects and adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Turn Protocol Compliance</measure>
    <time_frame>Subjects will be followed for the length of hospital stay which is expected to average 5 days.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary clinical efficacy endpoint is to assess the change in turning protocol compliance after implementation of the DynaSense system.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Pressure Ulcers</condition>
  <arm_group>
    <arm_group_label>DynaSense sensor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DynaSense sensor</intervention_name>
    <arm_group_label>DynaSense sensor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female 18 to 110 years of age;

          -  Inpatient currently on the unit and expected to remain for at least 12 hours;

          -  Able and willing to comply with the study procedures;

          -  Subject (or his/her agent) is able to read, understand, and provide Informed Consent
             in the English language.

        Exclusion Criteria:

          -  Subject is a female subject under the age of 60 who is pregnant, planning on becoming
             pregnant, or is currently breastfeeding.

               1. Any woman under the age of 60, must have a negative urine pregnancy test prior
                  to being enrolled in the study; OR

               2. Be postmenopausal for at least 2 years, OR

               3. have had a bilateral tubal ligations, OR

               4. have had a bilateral oophorectomy, OR

               5. have had a hysterectomy.

          -  Subjects with a known tape allergy or sensitivity to EKG leads or similar types of
             adhesives used in common medical products.

          -  Subjects who cannot have the patient sensor applied on the surface of the patient's
             anterior torso.

          -  Subjects who have a pacemaker or implantable cardiovascular-defibrillator (ICD).

          -  Subjects with dementia, Alzheimer's disease or other mental disabilities and
             incapacitation that would prevent the subject from providing written informed
             consent. If the subject is unable to provide informed consent due to mental
             incapacity, then the subject's Durable Power of Attorney may provide informed consent
             and sign the informed consent on behalf of the subject.

          -  Subjects who refuse to have an area of hair on their chest be clipped or shaved, if
             needed for patient sensor adhesion.

          -  Subjects, who in the opinion of the Principal Investigator, are at increased risk by
             participating in the clinical study.

          -  Subjects who have participated in another clinical study within the past 30 days or
             are currently participating in another clinical study at the time of screening.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Pezzani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>El Camino Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 10, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2013</firstreceived_date>
  <firstreceived_results_date>July 19, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pressure ulcers</keyword>
  <keyword>bed sores</keyword>
  <keyword>patient turn protocol</keyword>
  <keyword>patient movement</keyword>
  <keyword>patient monitoring</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pressure Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DynaSense Sensor</title>
          <description>All patients enrolled in the study were prescribed a Q2 hour (every 2 hour) turning protocol, as per the standard guidelines of the study site. In the context of the study, caregivers were not asked to turn patients any more or less frequently than what the study site's standard turning protocol required.
The rate of compliance with prescribed turning protocols was measured using the DynaSense System.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discharged earlier than anticipated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who successfully completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>DynaSense Sensor</title>
          <description>All subjects who successfully completed the study.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63" lower_limit="23" upper_limit="97"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="63"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Primary Endpoint</title>
        <description>The safety primary endpoint is to assess safety by documenting the number, type, and severity of side effects and adverse events.</description>
        <time_frame>Subjects will be followed for the length of hospital stay which is expected to average 5 days, or until resolution of ADE.</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>DynaSense Sensor</title>
            <description>All subjects enrolled in the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Safety Primary Endpoint</title>
            <description>The safety primary endpoint is to assess safety by documenting the number, type, and severity of side effects and adverse events.</description>
            <units>percentage of subjects with ADEs</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.86"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Turn Protocol Compliance</title>
        <description>The primary clinical efficacy endpoint is to assess the change in turning protocol compliance after implementation of the DynaSense system.</description>
        <time_frame>Subjects will be followed for the length of hospital stay which is expected to average 5 days.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>DynaSense Sensor</title>
            <description>All subjects who successfully completed the study.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Turn Protocol Compliance</title>
            <description>The primary clinical efficacy endpoint is to assess the change in turning protocol compliance after implementation of the DynaSense system.</description>
            <units>percentage turn compliance</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98" lower_limit="97" upper_limit="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Upon removal of the patient sensor (within 5 minutes of removal), the subject’s skin was assessed for any ADEs.</time_frame>
      <desc>If an ADE was present upon sensor removal, the subject’s skin was re-assessed approximately 1 hour later prior to hospital discharge when possible. If re-assessment was not possible prior to discharge, a follow-up telephone call was made to subjects to determine time to resolution.</desc>
      <group_list>
        <group group_id="E1">
          <title>DynaSense Sensor</title>
          <description>All subjects enrolled in the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema (Skin Redness)</sub_title>
                <description>Localized erythema (skin redness) following removal of patient sensor.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <description>Localized itching in skin region where patient sensor was removed.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Skin Irritation/Discomfort</sub_title>
                <description>Skin irritation and discomfort following removal of patient sensor.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barrett Larson, MD, Chief Medical Officer</name_or_title>
      <organization>Leaf Healthcare, Inc.</organization>
      <phone>650-701-3652</phone>
      <email>barrett.larson@leafhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
